About
Bioage Labs, Inc (NASDAQ:BIOA) — investor relations, events, news, and company updates on 6ix.
Latest News
Apr 21 2026
BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP
Apr 13 2026
BioAge Labs to Present at 25th Annual Needham Virtual Healthcare Conference
Mar 24 2026
BioAge Labs Reports Full Year 2025 Financial Results and Provides Business Updates from the Fourth Quarter of 2025
Feb 19 2026
BioAge Labs to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
Feb 9 2026
BLA for subcutaneous formulation of Leqembi® designated for Priority Review in China
Financials
Revenue
$8.99 M
Market Cap
$777.98 M
EPS
-2.24
Translate